Is Latuda Prolactin-Sparing?
Latuda (lurasidone) is relatively prolactin-sparing compared to most other antipsychotics, though it does cause modest prolactin elevations that are generally clinically insignificant.
Prolactin Effects Based on FDA Label Data
The FDA label for Latuda provides the most authoritative data on prolactin changes 1:
Adult Schizophrenia
- Median prolactin increase: +4.8 ng/mL (vs +0.1 ng/mL with placebo)
- Clinically significant elevations (≥5x upper limit of normal): Only 0.9% of patients
- Long-term data: Prolactin levels actually decreased over time (-0.9 ng/mL at 24 weeks, -5.3 ng/mL at 36 weeks)
Bipolar Depression
- Monotherapy: Median increases of +1.7 to +3.5 ng/mL depending on dose
- Adjunctive therapy: +2.8 ng/mL median increase
- Severe elevations: 0-0.4% of patients had prolactin ≥5x ULN
Adolescents
- Schizophrenia: +1.1 ng/mL median increase (vs +0.1 ng/mL placebo)
- Bipolar depression: +1.1 ng/mL median increase
- Severe elevations: 0-0.5% across studies
Comparative Context
Lurasidone sits in the middle tier of prolactin risk among antipsychotics. The Endocrine Society guidelines 2 provide comparative data showing hyperprolactinemia rates:
- High risk: Risperidone (81%), typical antipsychotics (38-90%)
- Moderate risk: Olanzapine (35%), ziprasidone (29%)
- Lurasidone: Not specifically mentioned in 2011 guidelines, but subsequent research shows it's comparable to or lower than olanzapine
Recent meta-analysis data 3 confirms lurasidone does not cause statistically significant prolactin changes compared to placebo in pediatric populations, unlike risperidone, paliperidone, and olanzapine which cause significant elevations.
Clinical Implications
The modest prolactin elevations with lurasidone rarely translate into clinical symptoms:
- Research shows minimal prolactin-related adverse events despite measurable increases 4, 5
- A 12-month study found "no clinically meaningful changes in prolactin" 4
- When switching from risperidone to lurasidone, patients experienced significant prolactin reductions (males: -11.2 ng/mL; females: -30.8 ng/mL) 6
Important Caveat
One case report 7 documented severe hyperprolactinemia in a 16-year-old girl on lurasidone, demonstrating that individual patients may experience atypical responses. This underscores the need for baseline and periodic prolactin monitoring regardless of the drug's general profile.
Practical Recommendations
Lurasidone is an appropriate choice when prolactin-sparing properties are desired, particularly:
- When switching from high-prolactin agents like risperidone or paliperidone
- In adolescents where pubertal development is a concern
- In patients with prior prolactin-related adverse effects
However, it is not truly "prolactin-neutral" like aripiprazole (which actually decreases prolactin 3). If absolute prolactin-sparing is required, aripiprazole remains the preferred option per Endocrine Society guidance 2.
Monitor prolactin at baseline and if symptoms develop (galactorrhea, menstrual irregularities, sexual dysfunction, gynecomastia) rather than routinely, given the low rate of clinically significant elevations.